Bioventus (BVS) Research & Development (2020 - 2026)

Bioventus (BVS) has 7 years of Research & Development data on file, last reported at $2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 18.07% year-over-year to $2.5 million; the trailing twelve-month figure through Mar 2026 stood at $11.6 million (down 19.3% YoY), and the FY2025 full-year result was $12.1 million, down 13.17% from the prior year.
• Research & Development for Q1 2026 stood at $2.5 million, down from $3.0 million in the prior quarter.
• Across five years, Research & Development topped out at $6.9 million in Q2 2022 and bottomed at $2.5 million in Q1 2026.
• The 5-year median for Research & Development is $3.3 million (2024), against an average of $3.9 million.
• The widest annual swing landed in 2022, when Research & Development soared 631.57%; it then plunged 46.62% in 2023.
• A 5-year view of Research & Development shows it stood at $5.9 million in 2022, then plunged by 45.14% to $3.3 million in 2023, then rose by 0.28% to $3.3 million in 2024, then decreased by 8.07% to $3.0 million in 2025, then declined by 17.96% to $2.5 million in 2026.
• The last three Research & Development figures came in at $2.5 million (Q1 2026), $3.0 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.

Peer Comparison